Clinical trial

Adaptive Study of IL-2 Dose Frequency on Regulatory T Cells in Type 1 Diabetes

NCT02265809

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2014-10-03

PhasePHASE1 / PHASE2

Study timeline

Study start (actual)2014-10-03Date precision: day

Registry last updated2018-08-21

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Type 1 Diabetesunresolved

Interventions

AldesleukinDRUG · verified · RxNorm: aldesleukin

Sponsors & collaborators

Cambridge University Hospitals NHS Foundation Trustlead sponsor

University of Cambridgecollaborator

Sir Jules Thorn Charitable Trustcollaborator

Juvenile Diabetes Research Foundationcollaborator

Wellcome Trustcollaborator

National Institute for Health Research, United Kingdomcollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02265809 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.